July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
March 2026 in “Mendeley Data” Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
17 citations
,
February 2011 in “Expert Opinion on Drug Safety” Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology”
2 citations
,
January 2025 in “touchREVIEWS in Endocrinology” SGLT2 inhibitors may help manage PCOS symptoms effectively.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
March 2026 in “Indian Journal of Dermatology” Baricitinib can cause excessive hair growth.
January 2011 in “Zhonghua zhongyiyao xuekan” Yiqi Huayu medicine can effectively reduce BPH in rats by lowering MMP-2 levels and blood vessel growth.
February 2024 in “Australasian journal of dermatology” Janus kinase inhibitors may help treat lichen planopilaris.
10 citations
,
June 2011 in “Movement Disorders” THAP1 gene changes do not affect DYT1 dystonia; finasteride may help reduce tics and OCD in Tourette syndrome.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
March 2026 in “Mendeley Data” Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
April 2025 in “Acta Dermato Venereologica” Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.